Return to search

Apogenix Raises Second Round

Apogenix GbBH, a German drug company focused on the targeted modulation of apoptosis, has raised EUR 27.5 million in second-round funding led by Dievini Hopp BioTech.



Apogenix GmbH, a biopharmaceutical company developing novel drugs based on the targeted modulation of apoptosis (programmed cell death), today announced the closing of its second financing round. The financing round totals EUR 27.5m (approx. USD 44m) and will be dedicated to the development of Apogenix